Rigel Pharmaceuticals, Inc. (RIGL) is flat to $3.11 in pre-market trading after it reported fiscal results for the fourth quarter. In its quarterly report, the drug developer said it earned ($0.25) per share, above the ($0.27) per share analysts were expecting. Revenue rose 43.5% to $8.25 million, well above views for $2.5 million. For the […]
View the full post at: Rigel Pharmaceuticals (RIGL) Reports Q4 Earnings: It’s A Beat